BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for cancer and other serious diseases, today announced that two-year follow-up data for ...

Data from patients with NHL treated in Phase 1 investigator-led study of GDA-201 demonstrates median duration of response of 16 months; safety outcomes consistent after two years Poster presentation ...

MOE Key Laboratory for Ferrous Metallurgy and Resources Utilization, WUST has the following research output in the current window (1 November 2024 - 31 October 2025) of the Nature Index. Click on ...

State Key Laboratory of Rare Earth Resources Utilization, CIAC CAS has the following research output in the current window (1 November 2024 - 31 October 2025) of the Nature Index. Click on Count to ...

Any regression of tumor (ART) within 12 weeks versus RECIST 1.1 response category as an intermediate endpoint to assess the activity of immune checkpoint inhibitors (ICIs) for metastatic urothelial ...

Optima: A phase II dose and volume de-escalation trial for high- and low-risk HPV+ oropharynx cancers. This is an ASCO Meeting Abstract from the 2017 ASCO Annual Meeting I. This abstract does not ...

BOSTON--(BUSINESS WIRE)-- Pear Therapeutics, Inc. (Nasdaq: PEAR), the leader in developing and commercializing software-based medicines, called prescription digital therapeutics (PDTs), today ...

The data show how disease-modifying therapies are changing outcomes for children with spinal muscular atrophy (SMA), a rare neuromuscular disease. A new analysis of the real-world outcomes of young ...